US contractor upholds Pacific Edge's Medicare ban

US contractor upholds Pacific Edge's Medicare ban
Pacific Edge has had a fresh blow to its hopes for access to the US Medicare market for Cxbladder diagnostic tests. (Image: Pacific Edge)
Greg Hurrell
Pacific Edge’s flagship Cxbladder cancer testing has been deemed as “not considered medically reasonable and necessary” by the company’s United States Medicare administrator. The statement is in a new proposed Local Coverage Determination (LCD) for Medicare and is a fresh blow for the company’s hopes to quickly regain long-term access to the Medicare system for its bladder cancer tests.Medicare is Pacific Edge’s largest customer.The new LCD was released overnight New Zealand time by Novitas, Pacific Edge...

More Markets

Vector agrees to sell LPG assets for $150m
Markets

Vector agrees to sell LPG assets for $150m

The deal is subject to regulatory approvals and commercial conditions.

Rebecca Howard 26 Jul 2024
ASX: Australian shares slide to a two-week low as tech drags
Markets

ASX: Australian shares slide to a two-week low as tech drags

Every sector of the Australian share market has lost ground.

AAP 26 Jul 2024
NZ sharemarket down 0.38%
Markets Market close

NZ sharemarket down 0.38%

The S&P/NZX 50 Index closed at the day’s low of 12,349.47, down 46.79 points or 0.38%.

Graham Skellern 26 Jul 2024
The Warehouse’s plight in five charts
Retail Charts

The Warehouse’s plight in five charts

The private equity bid shows the company’s future is still anyone’s guess.

Gregor Thompson 26 Jul 2024